TREATMENT WITH IMATINIB MESILAT IN CHRONIC MYELOGENOUS LEUKEMIA – OUR EXPERIENCE
<p>Background. Chronic myelogenous leukemia (CML) is a malignant clonal disorder of hematopoietic stem cell. In majority of patients we find reciprocal chromosomal translocation t (9.22) which result in fusion oncoprotein with tyrosine kinase activity. The normal ABL protein is involved in the...
Main Authors: | Mateja Grat, Joško Vučkovič |
---|---|
Format: | Article |
Language: | English |
Published: |
Slovenian Medical Association
2004-12-01
|
Series: | Zdravniški Vestnik |
Subjects: | |
Online Access: | http://vestnik.szd.si/index.php/ZdravVest/article/view/2419 |
Similar Items
-
Imatinib Mesylate Treatment in Chronic Myeloid Leukemia
by: Demet Çekdemir, et al.
Published: (2020-03-01) -
The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011-03-01) -
Imatinib Therapy in Chronic Myelogenous Leukemia and Thyroid Function Tests
by: Mohammad Ali Mashhadi, et al.
Published: (2014-09-01) -
Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
by: Hyun Jin Oh, et al.
Published: (2013-08-01) -
Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)